Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29347859 | 0.87 | ALDH1A1 (0.43) | ALDH1A1BTKRAB9AGAAKMT2A | |
| SCHEMBL24367131 | 0.78 | GPR35 (0.41) | RAB9AMAPTPOLBTSHR | |
| SCHEMBL20143373 | 0.76 | ALDH1A1 (0.62) | ALDH1A1RAB9AGAAKMT2AMAPT | |
| SCHEMBL29739561 | 0.75 | RAB9A (0.53) | ALDH1A1RAB9AGAAKMT2AMAPT | |
| SCHEMBL8705485 | 0.75 | RAB9A (0.53) | ALDH1A1RAB9AGAAKMT2AMAPT | |
| SCHEMBL22625559 | 0.75 | RAF1 (0.43) | ALDH1A1BTKRAB9ASMN1; SMN2TSHR | |
| SCHEMBL24879177 | 0.74 | WNT3A (0.53) | ALDH1A1 | |
| SCHEMBL22652926 | 0.74 | ALDH1A1 (0.42) | ALDH1A1BTKRAB9AMAPTSMN1; SMN2 | |
| SCHEMBL112442 | 0.73 | MGLL (0.55) | ALDH1A1BTKRAB9AKMT2AMAPT | |
| SCHEMBL25831982 | 0.73 | L3MBTL1 (0.41) | ALDH1A1RAB9AKMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ALDH1A1 128/4885BTK 2484/4885RAB9A 320/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | ALDH1A1 128/4885BTK 2484/4885RAB9A 320/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ALDH1A1 128/4885BTK 2484/4885RAB9A 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.